NC-LENOVO
28.2.2024 15:01:36 CET | Business Wire | Press release
Lenovo (HKSE: 992) (ADR: LNVGY) is rolling out a new solution to help customers extend the lifecycle of their devices with cost-efficient IT choices for a more sustainable future. Through Lenovo Certified Refurbished, organizations can deploy refurbished PCs that cater to their different computing needs and help manage their IT carbon footprint. Lenovo TruScale Device as a Service (DaaS) customers will also have more options to optimize their IT mix according to their unique economic and business needs, and with circularity in mind. Only Lenovo and accredited partners will offer the Lenovo certification, guaranteeing industry-leading quality devices that businesses can depend on.
“Environmental sustainability is a leading concern for businesses of every size, in every sector,” said Claudia Contreras, Executive Director of Global Sustainability Services for Lenovo. “Lenovo Certified Refurbished extends the lifecycle of our technology to improve ROI and help reduce waste, offering a solution that provides customers a purchase option to help support a more sustainable future. Certified Refurbished will help reduce e-waste, give devices new life, and positively contribute to the circular economy.”
Refurbishment, reuse, and recycling are key concepts in the circular economy, a resource and consumption system that helps mitigate waste. Lenovo is committed to implementing circular practices at every stage of the IT lifecycle, and as a leading global PC manufacturer, is uniquely qualified to help customers meet sustainability goals and embrace the benefits of circularity with confidence. Through the Lenovo 360 Circle community, channel partners are also aligned with collaborative actions to drive circular outcomes for customers and build a more sustainable future.
Lenovo’s 2023 Global Study of CIOs found that 60% of CIOs are turning towards as a Service (aaS) offerings for their tech stacks, including for sustainability management, and 62% said they find it challenging for their organization to reach sustainability goals. Outcome-based consumption models like Lenovo TruScale DaaS help businesses efficiently manage services, cost reduction, and waste reduction through a single source with the flexibility to scale as needed.
“Along with unified program management and streamlined financing, Lenovo TruScale DaaS offers lifecycle transformation approaches – including IT carbon footprint management and e-waste reduction – that help drive circularity and move customers closer to their sustainability goals while also helping to improve productivity and cost considerations. We’re excited to extend TruScale DaaS benefits to include options like Lenovo Certified Refurbished and help make IT circularity more achievable for customers,” said Anupam Garg, Lenovo Digital Workplace Solutions Offering Development leader.
Lenovo Certified Refurbished PCs undergo comprehensive data sanitization; expert testing to meet Lenovo’s high quality, security, and performance standards; and transparent, consistent quality grading. Access to Lenovo’s global support network provides added assurance that there is no compromise on security safeguards or PC performance, and that the refurbished devices will have a productive operational life with up to three years of standard warranty (with the option to upgrade). Lenovo Certified Refurbished PCs can help customers lower technology outlays while retaining a high level of performance and functionality, and refurbished devices may open a wider pool of options for budget-conscious organizations.
Lenovo Certified Refurbished PCs will be available initially in Denmark, France, Germany, and the U.K., with a planned global rollout. Lenovo Certified Refurbished is the latest in a series of Lenovo offerings that aid customers in their sustainability journeys. Learn more about Lenovo’s Sustainability Solutions.
About Lenovo
Lenovo is a US$62 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, employing 77,000 people around the world, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company by further expanding into growth areas that fuel the advancement of ‘New IT’ technologies (client, edge, cloud, network, and intelligence) including server, storage, mobile, software, solutions, and services. This transformation together with Lenovo’s world-changing innovation is building a more inclusive, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992)(ADR: LNVGY). To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub.
LENOVO and TRUSCALE are trademarks of Lenovo. ©2024 Lenovo. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228104727/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom